ERBB2 and cancer: The role as a prognostic biomarker of HER2 is still doubtful; indeed some studies show an association of HER2 with a worse prognosis and a more aggressive disease; others contrariwise do not find a significant difference in prognosis between HER2 positive and HER2 negative cancers [76, 80–82, 91, 93–103].